
Developing breakthrough AXL therapeutics to improve patients’ lives
COMPANY PRESENTATIONS
Nordic Healthcare Conference 2022, 15 December 2022
15 December 2022
SCIENTIFIC PUBLICATIONS
Cell Report Medicine, Huiyu Li et al.
15th March 2022
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
BerGenBio’s lead candidate, bemcentinib, is in Phase II clinical testing in patients with NSCLC, AML and COVID-19. As of the end of 2021, bemcentinib had been studied in over 600 patients, demonstrating its safety as a monotherapy and in combination with chemotherapy and immune checkpoint inhibition. This large safety database positions us well to advance the development of bemcentinib towards the market. Clinical data generated with bemcentinib in multiple Phase I and Phase II trials to date, confirm its potential utility as a therapy in cancer and for the treatment of COVID-19. Based on preclinical and early clinical data, we also believe bemcentinib may have the ability to enhance outcomes when combined with immunotherapy in NSCLC. Taken together, our initial data form the basis of BerGenBio’s preparations for the late-stage clinical strategy for bemcentinib.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).
Explore BerGenBio’s pipelineLatest News
BerGenBio Announces the Establishment of Oncology Scientific Advisory Board
– Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC – BERGEN, Norway, February 2, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,
Read moreBerGenBio Reports Third Quarter 2022 Financial Results and Provides Business Update
– Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients –– Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations –– Strengthened
Read moreBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
– Study will assess bemcentinib in combination with current standard of care for 1st line NSCLC – – Approximately 20% of NSCLC patients have STK11 mutations – – First
Read moreBERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
BERGEN, Norway, September 27, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Oslo University Hospital
Read more